On Aug. 28, 2025, Teva Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of a generic version of Saxenda^®1 (liraglutide injection).

Liraglutide Injection is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:

Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition. Liraglutide injection should be used with a reduced calorie diet and increased physical activity. Liraglutide injection is not recommended for people who also take liraglutide or other medicines called glucagon-like peptide-1 (GLP-1) receptor agonists.